Siplizumab Biosimilar

Siplizumab is a humanized monoclonal antibody biosimilar expressed in CHO cells, targeting CD2/LFA-2, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Siplizumab has been shown to cause depletion of T-cells. It is therefore considered to be an immunomodulator in clinical settings where the depletion of T-cells may have clinical benefits, such as certain autoimmune diseases and T-cell cancers. In addition, preclinical studies have also suggested that siplizumab, by binding to the CD2 receptor, may selectively produce cell death and reduce cancerous cells.

Target	CD2/LFA-2
Research Area	Humanized Monoclonal Antibodies, Biosimilars
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1 Kappa
Form	Liquid
Purity	> 95% (SDS-PAGE)
Purification	Purified from cell culture supernatant by Protein A/G chromatography.
Storage	Store at 4°C for up to 2 weeks. Aliquot and store at -20°C for long term storage. Avoid repeated freeze/thaw cycles.
Shelf Life	12 months.
UniProt Primary AC	P06729 (UniProt, ExPASy)
UniProt Entry Name	CD2_HUMAN
Buffer	0.01 M PBS, pH 7.4.
CAS Number	288392-69-8
Concentration	2.93 mg/ml
Availability	Shipped within 5-10 working days.
Note	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.

Research Articles on CD2/LFA-2

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue